All prohibited substances in this class are non-Specified Substances.
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS, INCLUDING, BUT NOT LIMITED TO:
1.1 ERYTHROPOIETIN-RECEPTOR AGONISTS, E.G.
- Darbepoetins (dEPO)
- Erythropoietins (EPO)
- EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]
- EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide)
1.2 HYPOXIA-INDUCIBLE FACTOR (HIF) ACTIVATING AGENTS, E.G.
- Cobalt
- Daprodustat (GSK1278863)
- IOX2
- Molidustat (BAY 85-3934)
- Roxadustat (FG-4592)
- Vadadustat (AKB-6548)
- Xenon
1.3 GATA INHIBITORS, E.G.
- K-11706
1.4 TRANSFORMING GROWTH FACTOR -BETA (TGF-Β) SIGNALING INHIBITORS, E.G.
- Luspatercept
- Sotatercept
1.5 INNATE REPAIR RECEPTOR AGONISTS, E.G.
- Asialo EPO
- Carbamylated EPO (CEPO)
2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS
2.1 CHORIONIC GONADOTROPHIN (CG) AND LUTEINIZING HORMONE (LH) AND THEIR RELEASING FACTORS IN MALES, E.G.
- Buserelin
- Deslorelin
- Gonadorelin
- Goserelin
- Leuprorelin
- Nafarelin
- Triptorelin
2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS, E.G.
- Corticorelin
2.3 GROWTH HORMONE (GH), ITS ANALOGUES AND FRAGMENTS, INCLUDING, BUT NOT LIMITED TO:
- growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon
- growth hormone fragments, e.g. AOD-9604 and hGH 176-191
2.4 GROWTH HORMONE RELEASING FACTORS, INCLUDING, BUT NOT LIMITED TO:
- growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
- growth hormone secretagogues (GHS) and its mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin]
- GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)]
3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS
INCLUDING, BUT NOT LIMITED TO:
- Fibroblast growth factors (FGFs)
- Hepatocyte growth factor (HGF)
- Insulin-like growth factor 1 (IGF-1) and its analogues
- Mechano growth factors (MGFs)
- Platelet-derived growth factor (PDGF)
- Thymosin-β4 and its derivatives e.g. TB-500
- Vascular endothelial growth factor (VEGF)
and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
WKSF Sponsor for 2022 Anti-Doping Campaign
![](https://wksf.site/wp-content/uploads/2022/03/IMG_20220216_105902_973.jpg)